ClinicalTrials.gg
CompletedNCT05849883Updated May 9, 2023

Bioequivalence Study of 20 mg Omeprazole Capsules in Indonesia Healthy Subject

An interventional study of Omeprazole 20 mg Capsules in Drug Use, sponsored by PT Kalbe Farma Tbk. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-09.

Sponsored by PT Kalbe Farma Tbk · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Dec 2020, registered Feb 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 44 Years
Sex
All
01

Study summary

The study was conducted to investigate whether 20 mg omeprazole capsules manufactured by PT. Dankos Farma for PT. Hexpharm Jaya is bioequivalent to its reference product, 20 mg Losec® capsules manufactured by AstraZeneca AB, Sweden, imported by PT. AstraZeneca Indonesia.

Read the detailed description

Thirty six healthy subjects were given a single dose of 20 mg omeprazole capsules or 20 mg Losec® capsules with 240 mL of water. Then the blood samples for omeprazole were drawn and analyzed using LCMS/MS. All subjects sample plasma were analyzed for pharmacokinetic evaluation.

02

Conditions studied

  • Drug Use

Keywords

  • Omeprazole
  • Bioequivalence Study
03

In context

Lead sponsor

This is the only study on the registry with PT Kalbe Farma Tbk as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 44 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

The inclusion criteria were healthy male or female subjects who/with:

  • had read the subject information and signed documents
  • age range from 18 - 55 years
  • between 18-25 kg/m2
  • had a normal
  • had the blood pressure within normal range (systolic 90-120 mmHg and diastolic 60-80 mmHg)
  • had the heart rate within normal range (60 - 100 bpm)
  • had absence of significant disease or abnormal laboratory values on laboratory evaluation, medical history or physical examination during screening.
  • accepted to use protection (condom) before any intercourse with their spouse throughout the study

Excluded from the study were:

  • those who were pregnant and/or nursing women (for women).
  • those with history of or to omeprazole, or other proton pump inhibitor drugs or other ingredients in the drugs or a history of serious allergic reaction to any drug, a significant allergic disease, or allergic reaction.
  • those with a history or presence of medical condition which might significantly influence the pharmacokinetic of the study drug, e.g. chronic gastrointestinal disease, diarrhea, gastric surgery, renal insufficiency, hepatic dysfunction or cardiovascular disease.
  • those with a history or presence of any coagulation disorder or clinically significant hematology abnormalities.
  • those who were using any medication (prescription or non-prescription drug, food supplement, herbal medicine), particularly the medication known to affect the pharmacokinetic of the study drug, within one week prior to the drug administration day.
  • those who had participated in any clinical study within 3 months prior to the study (\<90 days).
  • those who had donated or lost 300 ml (or more) of blood within 3 months prior to the study.
  • those who smoked more than 10 cigarettes a day
  • those who were reactive to SARS CoV-2 test.
  • those with a history of travelling to another city within the last 14 days
  • those with a history of direct contact with a COVID-19 positive person in the subject's neighborhood
  • those with a history or present of sore throat, fever (with temperature more than 37°C) or dyspnea with in the last 14 days
  • those who were positive to , , and tests (to be kept confidential).
  • those with a history of drug or alcohol abuse within 12 months prior to screening for this study.
  • those who were unlikely to comply with the protocol, e.g uncooperative attitude, inability to return for follow up visits, poor venous access.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Omeprazole 20 mg capsules

    Subjects were given a single dose of 20 mg omeprazole of either formulation (test or reference) with 240 ml of water

    Drug: Omeprazole 20 mg Capsules

  • Active comparator
    Losec® 20 mg capsules

    Subjects were given a single dose of 20 mg omeprazole of either formulation (test or reference) with 240 ml of water

    Drug: Omeprazole 20 mg Capsules

Interventions

  • Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production

    Also known as: Losec® 20 mg capsules

06

What researchers measure

Primary outcomes

  1. Geometric Mean Ratio of Cmax

    The ratio between maximum concentration of test drug and reference drug after drug administration

    Time frame: before dosing and at 15, 30, 45, 60, 75, 90, 105 minutes, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 5, 6, 8, and 10 hours after drug administration

  2. Geometric Mean Ratio of AUCt

    The ratio between area under curve from 0 to 10 hours of test drug and reference drug

    Time frame: before dosing and at 15, 30, 45, 60, 75, 90, 105 minutes, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 5, 6, 8, and 10 hours after drug administration

Secondary outcomes

  1. Pharmacokinetics Parameter of Cmax

    Maximum plasma concentration (Cmax)

    Time frame: before dosing and at 15, 30, 45, 60, 75, 90, 105 minutes, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 5, 6, 8, and 10 hours after drug administration

  2. Pharmacokinetics Parameter of AUCt

    Area Under Curve from 0 to 10 hours (AUCt)

    Time frame: before dosing and at 15, 30, 45, 60, 75, 90, 105 minutes, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 5, 6, 8, and 10 hours after drug administration

07

Study locations

1 site
  • PT Pharma Metric Labs
    Jakarta Pusat, DKI Jakarta 10520, Indonesia
08

References and documents

Publications

  • Kim YK, Yoon S, Yu KS, Kim BH, Yim SV. A bioequivalence study of two omeprazole formulations in healthy male volunteers. Int J Clin Pharmacol Ther. 2016 Nov;54(11):928-934. doi: 10.5414/CP202580. PubMed 27615007 ↗
  • Cederberg C, Andersson T, Skanberg I. Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol Suppl. 1989;166:33-40; discussion 41-2. doi: 10.3109/00365528909091241. PubMed 2690330 ↗
  • Oosterhuis B, Jonkman JH. Omeprazole: pharmacology, pharmacokinetics and interactions. Digestion. 1989;44 Suppl 1:9-17. doi: 10.1159/000200098. PubMed 2691315 ↗
  • Dubcenco E, Beers-Block PM, Kim LP, Schotland P, Levine JG, McCloskey CA, Bashaw ED. A Proton Pump Inhibitor in the Reformulation Setting: Bioequivalence and Potential Implications for Long-Term Safety. Clin Transl Sci. 2017 Sep;10(5):387-394. doi: 10.1111/cts.12475. Epub 2017 Jun 15. PubMed 28618191 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Jan 2021, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2023
First posted
May 9, 2023
StartActual
Dec 10, 2020
Primary completionActual
Jan 14, 2021
CompletionActual
Feb 3, 2021
Last update
May 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05849883
Lead sponsor
PT Kalbe Farma Tbk
Collaborators
PT Pharma Metric Labs
Responsible party
Sponsor
First posted
May 9, 2023
Start date
Dec 10, 2020
Primary completion
Jan 14, 2021
Completion
Feb 3, 2021
Last update
May 9, 2023

Study contacts

Frans D Suyatna
principal investigator · PT Pharma Metric Labs
I Gusti Putu Bagus Diana Virgo
study director · PT Pharma Metric Labs

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omeprazole

Start the discussion